<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Subramaniyan B</submitter><funding>National Institutes of Health</funding><pagination>102629</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12719973</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>63</volume><pubmed_abstract>Mutations in nuclear factor erythroid 2-related factor 2 (NFE2L2 or NRF2) occur in 10-22 % of esophageal squamous cell carcinoma (ESCC) cases and result in NRF2 activation, promoting tumor progression, and therapeutic resistance. Although previous studies suggested a link between NRF2 and kinases, specific kinases responsive to NRF2 activation remain to be fully identified. Using protein phosphorylation profiling and kinase activity profiling, we identified phosphatidylinositol 3-kinase (PI3K) pathway as a downstream effector in NRF2&lt;sup>W24C&lt;/sup>-KYSE70 cells compared to isogenic NRF2&lt;sup>null&lt;/sup>-KYSE70 cells. AREG, pEGFR, PIK3CA, pAKT, p-S6, and p-PTEN were downregulated in NRF2 deficient cells. Notably, NRF2 deficiency sensitized ESCC cells to EGFR, PIK3CA, and AKT inhibitors. Co-tr</pubmed_abstract><journal>Translational oncology</journal><pubmed_title>The PI3K pathway is a downstream effector of NRF2 activation in the esophagus.</pubmed_title><pmcid>PMC12719973</pmcid><funding_grant_id>AA030026</funding_grant_id><funding_grant_id>R01 CA244236</funding_grant_id><pubmed_authors>Xiong Z</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Bui-Linh C</pubmed_authors><pubmed_authors>Subramaniyan B</pubmed_authors><pubmed_authors>Spitz F</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Paiboonrungruang C</pubmed_authors></additional><is_claimable>false</is_claimable><name>The PI3K pathway is a downstream effector of NRF2 activation in the esophagus.</name><description>Mutations in nuclear factor erythroid 2-related factor 2 (NFE2L2 or NRF2) occur in 10-22 % of esophageal squamous cell carcinoma (ESCC) cases and result in NRF2 activation, promoting tumor progression, and therapeutic resistance. Although previous studies suggested a link between NRF2 and kinases, specific kinases responsive to NRF2 activation remain to be fully identified. Using protein phosphorylation profiling and kinase activity profiling, we identified phosphatidylinositol 3-kinase (PI3K) pathway as a downstream effector in NRF2&lt;sup>W24C&lt;/sup>-KYSE70 cells compared to isogenic NRF2&lt;sup>null&lt;/sup>-KYSE70 cells. AREG, pEGFR, PIK3CA, pAKT, p-S6, and p-PTEN were downregulated in NRF2 deficient cells. Notably, NRF2 deficiency sensitized ESCC cells to EGFR, PIK3CA, and AKT inhibitors. Co-tr</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-09T04:57:31.434Z</modification><creation>2026-06-09T03:07:35.494Z</creation></dates><accession>S-EPMC12719973</accession><cross_references><pubmed>41344057</pubmed><doi>10.1016/j.tranon.2025.102629</doi></cross_references></HashMap>